89biologo.png
89bio Announces Positive Topline Results from its Phase 1b/2a Trial of BIO89-100 in NASH
14. September 2020 07:01 ET | 89bio, Inc.
All dose groups achieved statistically significant reductions in liver fat, with relative reductions of up to 60% versus baseline and up to 70% versus placebo     Favorable safety and...
89biologo.png
89bio Announces Proposed Public Offering of Common Stock
06. Juli 2020 06:30 ET | 89bio, Inc.
SAN FRANCISCO, July 06, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89biologo.png
89bio Announces Closing of Enrollment in its Phase 1b/2a NASH Trial and Reports New Preclinical Data Confirming BIO89-100’s Mechanism of Action Via Potent FGF Receptor Agonism
13. April 2020 08:30 ET | 89bio, Inc.
- Closed enrollment in its Phase 1b/2a NASH trial with 98% of patients enrolled and delays initiation of its SHTG trial due to the COVID-19 pandemic; Reaffirms guidance for NASH trial topline data in...
89biologo.png
89bio Appoints Healthcare Industry Veteran Steven Altschuler, M.D., as Chairman of the Board of Directors
25. März 2020 16:05 ET | 89bio, Inc.
SAN FRANCISCO, March 25, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89biologo.png
89bio Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
18. März 2020 16:05 ET | 89bio, Inc.
- BIO89-100 Phase 1b/2a NASH study on track for topline data in 2H20 - - Initiation of Phase 2 SHTG study planned in 1H20 - SAN FRANCISCO, March 18, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq:...
89biologo.png
89bio to Present at the SVB Leerink 9th Annual Global Healthcare Conference
21. Februar 2020 16:05 ET | 89bio, Inc.
SAN FRANCISCO, Feb. 21, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...